The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

Ozempic has been approved by the FDA for treating type 2 diabetes and chronic kidney disease and ... Studies suggest GLP-1 ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Beyond weight loss: protecting muscle with GLP-1s. Dr Almandoz shares strategies to preserve muscle, optimize body composition, and enhance health outcomes during GLP-1 therapy.

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments ... people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050.